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Abstract 
Purpose: To synthesize novel tris-diamine-derived transition metal complexes of flurbiprofen 
M(C2H8N2)3 (fp)2 and M(C3H10N2)3 (fp)2, and to evaluate their acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE) inhibitory activities. 
Method: Tris-diamine-derived transition metal complexes of Co(II), Ni(II), and Mn(II) were synthesized 
and characterized using ultraviolet-visible (UV-Vis) spectroscopy, Fourier transform-infrared (FT-IR) 
spectroscopy, elemental analysis, magnetic susceptibility, conductivity measurement and single crystal 
x-ray analysis. The synthesized complexes were also evaluated for their AChE and BChE inhibitory 
activities. 
Results: Based on magnetic susceptibility and electronic studies, the synthesized complexes 
possessed distorted octahedral geometry. Conductance measurements indicated that diamine-derived 
metal complexes of flurbiprofen were electrolytes, whereas, simple metal complexes of flurbiprofen 
were non-electrolytes. The structure of Ni (C2H8N2)3 (fp)2 was also confirmed by single crystal x-ray 
analysis. The synthesized metal complexes exhibited moderate-to-very good inhibition of AChE and 
BChE. In vitro assays revealed that Ni complexes were most active, with the least half-maximal 
inhibitory concentration (IC50) values against AChE and BChE, compared to Co and Mn complexes. 
Furthermore, 1, 2-diaminoethane-derived complexes were more potent, with lower IC50 values against 
both AChE and BChE, compared to 1,3-diaminopropane-derived complexes. Among the complexes, 4a 
and 5a revealed significant cholinesterase inhibitory activities relative to the standard drug, galantamine. 
Conclusion: All the synthesized metal complexes are active against AChE and BChE, but only 4a and 
5a are more active than the standard drug, galantamine, indicating their potential for drug development. 
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It has been estimated that worldwide, 35 million 
people suffer from Alzheimer Disease (AD), and 
that this number is expected to quadruple in the 
next 50 years [1,2]. The likely cause of this 
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disease is accumulation of heavy metals in the 
brain, oxidative stress, aging as well as variation 
in the level of cholinesterases.  
 
The primary pharmacological strategies for the 
control of AD involve enhancement of cholinergic 
neurotransmission by reducing the rate of 
decomposition of acetylcholine (ACh) at 
synapses through the use of acetyl-
cholinesterase inhibitors (AChEIs) [3,4]. 
Tetrahydroacridine and its derivatives are 
acclaimed as the first synthetic AChEIs, whereas 
Ladostigil which possesses neuro-protective 
cholinesterase inhibitory properties, was 
developed for AD [5,6]. Recently, Galantamine, 
Rivastigmine and Donepezil were recommended 
for inhibiting the activity of cholinesterases for the 
maintenance and control of neural dysfunctions 
associated with AD [7-9]. 
 
Derivatives of NSAID-AChEI have recently been 
prepared to target neuro-inflammation and 
vesicant-induced inflammation [10]. This was 
based on their effectiveness against 
inflammatory disorders through inhibition of 
cyclooxygenase and activation of the cholinergic 
anti-inflammatory pathway [11]. Some metal 
chelates of glycine, ethylene-diamine, 1, 3-
diaminopropane and tetramethyl-
ethylenediamine have been reported as 
cholinesterase inhibitors [12,13]. The AChEIs are 
associated with side effects such as diarrhea, 
nausea, anorexia, fatigue, rhinitis, asthenia, leg 
cramps, insomnia, dizziness, and vomiting. 
However, pharmacological evaluation of 
synthesized drugs, docking and in vivo studies 
could provide better alternative drugs for 
cholinesterase inhibition [14,15].  
 
In the present study which is a continuation of 
the search for new potent cholinesterase 
inhibitors [16], and keeping in view the 
cholinesterase inhibitory properties of NSAIDs-
diamines, a relatively new class of flurbiprofen 
and its transition metal complexes with diamines 
(1,2-diaminoethane and 1,3-diaminopropane) 






Analytical grade chemicals and reagents 
including metal salts (nickel acetate, cobalt 
acetate, manganese acetate), ethylene-diamine 
(1, 2-diaminoethane), propane-diamine (1, 3-
diaminopropane) and solvents purchased from 
Merck Millipore, England were used as received. 
Flurbiprofen acid was purchased from Sigma 
Aldrich, England. The progress of the reactions 
was monitored by using TLC plates. Shimadzu 
(FT)-IR-8400S spectrophotometer was used for 
recording infrared spectra in the region 4000 - 
400 cm-1 with KBr disc, while Jenway 6505 
UV/Visible double beam spectrophotometer was 
employed for UV-visible spectra. Micro analytical 
data (C, H, N, %) were obtained using Elemental 
Analyzer (Perkin Elmer, USA). Molar 
conductance of the complexes at 25 oC was 
measured with Inolab Conductivity Bridge 720. 
Magnetic susceptibility was calculated with 
Stanton SM12/S Gouy’s balance calibrated using 
Hg[Co(NCS)4]. 
 
General procedure for the synthesis of metal 
flurbiprofen complexes (3a-3c) 
 
Flurbiprofen acid 1 (2.44 g, 0.01 mole) was 
dissolved in 20 ml de-ionized water by adding 
KOH (0.56 g, 0.01 mole) until the solution 
became clear, forming potassium salt of 
flurbiprofen. To this solution, aqueous solutions 
of metal acetate salts (Ni, Co and Mn acetates, 
0.005 mole) were added drop-wise with constant 
stirring in a round bottom flask, and stirring was 
continued for further 15 min at 40 oC. The 
precipitates of flurbiprofen metal complexes (3a-
3c) formed were filtered, washed with ethanol 
and distilled water, and dried at room 
temperature. 
 
Synthesis of tris (1, 2-diaminoethane) metal 
flurbiprofen complexes (4a-4c) 
 
To each stirred suspension of synthesized 
flurbiprofen metal complexes (3a-3c) in 
ethanol/water (1:1 v:v) solution, 2.0ml of 1,2-
diaminoethane (0.03 mole) was added. The 
reaction mixtures were stirred for 15-20 min at 
room temperature until they became clear with 
characteristic colors. Slow evaporation of these 
solutions produced the desired solid products tris 
(1, 2-diaminopropane)-flurbiprofen metal 
complexes (4a-4c). 
 
Synthesis of tris (1, 3-diaminopropane) metal 
flurbiprofen complexes (5a-5c) 
 
To each stirred suspension of synthesized 
flurbiprofen metal complexes (3a-3c) in 
ethanol/water (1:1, v:v) solution, 1.68 ml of 1,3-
diaminopropane (0.02 mole) was added, and 
reaction mixtures were stirred for 15-20 min at 
room temperature until they became clear with 
characteristic colors of the metal complexes. 
Slow evaporation of these solutions produced the 
desired solid tris (1,3-diaminopropane)-
flurbiprofen metal complexes (5a-5c). 
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Single crystal x-ray analysis 
 
For compound Ni (C2H8N2)3 (fp)2 (4a), x-ray 
measurements were calculated on a Bruker 
kappa APEXII (CCD) diffractometer equipped 
with a graphite-mono-chromated Mo-Kα 
(λ…0.71073 Å) radiation. For data collection 
multi-scan, absorption correction and  scans 
were applied. The structure of 4a was resolved 
by using SHELXS-97. Geometrical 
considerations were made for hydrogen atoms 
and methyl groups defined as rigid groups which 
could rotate freely. Final structural refinement on 
F2 was carried out by least-squares, full-matrix 
techniques using SHELXL-97 [17,18]. ORTEP 
diagram of the molecule was obtained by using 
Mercury software of Cambridge Crystallographic 
Resources. 
 
Determination of AChE and BChE inhibitory 
activities 
 
Standard colorimetric procedures were used in 
assaying the inhibitory activities of the complexes 
[16,19].  Acetylthiocholine iodide, butyryl-
thiocholine iodide, AChE, BChE and DTNB 
(Sigma-Aldrich) were used. The concentration of 
each coloured reaction product was measured at 
412 nm in a μQuant microplate 
spectrophotometer (MQX200). Galantamine 
hydrobromide from Lycoris Sp. (Sigma-Aldrich) 
and Donepezil were used as reference drugs. 
Stock solutions of the synthesized metal 
complexes were prepared in 0.1 M phosphate 
buffer, pH 8. Controlled amount of DTNB 
(Ellman’s reagent), metal complex and AChE or 
BChE (0.03 U/ml) were prepared and allowed to 
react by pre-incubating at 30 °C for 10 min. 
Thereafter, 1 mM ATCI or BTCI was added, and 
the reaction mixture was incubated further for 15 
min. Absorbance was read thrice at 412 nm, and 
IC50 values of the compounds were calculated by 




All the synthesized metal complexes exhibited 
good-to-excellent yields. The purity of the 
complexes was measured through sharp melting 
point (m.pt.) determination. The synthesized 
metal complexes were characterized using single 
FT-IR, UV-VIS spectroscopy, conductivity 
measurements, elemental analysis, magnetic 
susceptibility and single crystal X-ray analysis. 
Distorted octahedral geometry was proposed for 
all the metal complexes based on magnetic 
susceptibility and electronic spectra. High value 
of conductance for diamine-derived metal 
complexes confirmed their ionic nature.  Physical 
data and elemental (CHNS/M) analysis of the 
synthesized complexes were consistent with the 
proposed structures. The scheme of the 


























































 ( 1 :1 )
M = Mn, X =en(4c), pd(5c)
M = Co, X = en(4b), pd(5b)
M = Ni, X = en(4a), pd(5a)
pd = propanediamine or 
(1,3 diaminopropane)






























Figure 1: Scheme for the synthesis of tris-diamine-derived metal flurbiprofen complexe





Light green solid, yield = 83%, m.pt. =165-167oC; 
analytically calculated values for C30H28F2O6Ni 
(%): C =  61.99, H= 4.86; found: C= 61.89, H = 
4.90; selected FT-IR data (KBr, cm-1): ῡ(M←H2O) 
= 3683 cm-1, ῡ(M←O) = 468 cm-1, ῡ (COO) 
1667cm-1,ῡ (C-H) = 2794 cm-1 and 
disappearance of broad ῡ (O-H) peak of (COOH) 
at 3200 – 3400;  λmax (cm-1) = 12713, 18274, 




Light pink solid, yield = 71%, m.pt. = 153-155oC; 
analytically calculated values for C30H28F2O6Co 
(%): C= 61.97, H= 4.85; found: C= 61.95, H= 
4.84; selected FT-IR data (KBr, cm-1): ῡ 
(M←H2O) 3620 cm-1, ῡ(M←O)478 cm-1, ῡ (COO) 
1673cm-1,ῡ (C-H) =2824cm-1 and disappearance 
of broad ῡ (O-H) peak of (COOH) at 3200-3400, 
λmax (cm-1) = 14467, 21332, 17384-17565; Ω-




White solid, yield = 87%, m.pt. = 150-152oC; 
analytically calculated values for C30H28F2O6Mn 
(%): C= 62.40, H = 4.89; found: C = 62.32, H= 
4.88; selected FT-IR data (KBr, cm-1): ῡ 
(M←H2O) 3655 cm-1, ῡ (M←O) 443 cm-1, ῡ 
(COO) 1682 cm-1,ῡ(C-H) 2817cm-1 and 
disappearance of broad ῡ (O-H) peak of (COOH)  
at 3200 - 3400, λmax (cm-1) = 16645, 20755, 
24532, 27234; Ω-1cm2mol-1) = 26, µeff  = 1.9 
 
Ni (C2H8N2)3 (fp)2 (4a) 
 
Violet crystals, yield =78%, m.pt. = 82-284oC); 
analytically calculated values for C36H50F2N6O4Ni 
(%): C = 59.43, H = 6.93, N = 11.55; found: C = 
59.35, H = 6.94, N = 11.54; selected FT-IR data 
(KBr, cm-1): ῡ (M←N) = 501cm-1, ῡ (CH) 
=2841cm-1; disappearance of broad ῡ (O-H) peak 
of (COOH) at 3200 - 3400 cm-1 region, and 
disappearance of ῡ (M←O) peak at 440-490 cm-1 
region,; λmax (cm-1) = 18532, 22247, 29408; Ω-
1cm2mol-1) = 186, µeff = 3.3 
 
Co (C2H8N2)3 (fp)2 (4b) 
 
Greenish-brown solid, yield = 80%, m.pt. = 273-
275oC; analytically calculated values for 
C36H50F2N6O4Co (%): C = 59.41; H = 6.93; N = 
11.55; found: C = 59.38; H = 6.97; N = 11.52; 
selected FT-IR data (KBr, cm-1): ῡ (M←N) = 569 
cm-1; ῡ (CH) = 2819cm-1; disappearance of  ῡ 
(M←O) peak at 440-490 cm-1 region and  broad 
ῡ (O-H) peak of (COOH) at 3200-3400 cm-1 
region; λmax (cm-1) = 14797, 19456, 21447 – 
21673; Ω-1cm2mol-1) = 174, µeff = 1.8 
 
Mn (C2H12N2)3 (fp)2(4c) 
 
Dark brown solid, yield = 77%, m.pt.= 266-
268oC;; analytically calculated values for 
C36H50F2N6O4Mn (%): C = 59.74, H = 6.96, N 
=11.61; found: C = 59.69, H = 6.97, N = 11.63; 
selected FT-IR data (KBr, cm-1): ῡ (M←N) = 530 
cm-1, ῡ (CH) = 2878cm-1; disappearance of broad 
ῡ (O-H) peak of ῡ (COOH) at 3200 - 3400 region 
and ῡ (M←O)peak in 440-490 cm-1, λmax (cm-1) = 
18354, 20862, 25568, 29421; Ω-1cm2mol-1) = 
163, µeff = 2.1 
 
Ni (C3H10N2)3 (fp)2  (5a) 
 
Violet crystals, yield = 85%, m.pt. = 272-274oC), 
analytically calculated values for C39H54F2N6O4Ni 
(%): C = 61.03; H = 7.09, N = 10.95; found: C = 
60.90, H = 7.03, N = 11.03; selected FT-IR data 
(KBr, cm-1): ῡ (M←N) = 501 cm-1, ῡ (CH) = 2834 
cm-1 and disappearance of ῡ (M←H2O), ῡ 
(M←O) at 440 - 490 cm-1 and broad ῡ (O-H) peak 
at 3200-3400 cm-1, λmax (cm-1) = 18521, 22234, 
29397, Ω-1cm2mol1) = 175, µeff = 3.3. 
 
Co (C3H10N2)3 (fp)2 (5b) 
 
Greenish-brown solid, yield = 75%, m.pt. = 265-
267oC), analytically calculated values for 
C39H54F2N6O4Co (%): C = 61.01, H = 7.09, N = 
10.95; found: C = 60.11,  H = 7.00, N = 10.91; 
selected FT-IR data (KBr, cm-1):ῡ (M←N) = 569 
cm-1, ῡ (CH) = 2861cm-1 and disappearance of ῡ 
(M←O), ῡ (M←H2O) = peaks and broad ῡ (O-H) 
peak at 3200-3400 cm-1 region, λmax(cm-1) = 
14782, 19435, 21427-21616; Ω-1cm2mol-1) = 169, 
µeff = 1.8 
 
Mn (C3H12N2)3 (fp)2(3c) 
 
Dark brown compound, yield =73%; analytically 
calculated values for C39H54F2N6O4Mn (%): C = 
61.33, H = 7.13, N = 11.00; found: C = 61.26; H 
= 7.08, N = 11.30; selected FT-IR data (KBr, cm-
1): ῡ (M←N)= 530 cm-1, ῡ  (CH) = 2863 cm-1 and 
disappearance of ῡ (M←O) and ῡ (M←H2O) 
peaks, and broad ῡ (O-H) peak at 3200 - 3400 
cm-1 region; λmax (cm-1) = 18366, 20887, 25589, 




After refinement, the crystal data of the 
compound Ni(C2H8N2)3 (fp)2 (4a) showed 
formation of a complex consisting of 2 types of 
ionic moieties (Figure 2, Table 1).  
 




Figure 2: ORTEP diagram of Ni(C2H8N2)3 (fp)2 (4a) (CCDC #1569831) 
 
Table 1: Crystal data and structure refinement for (4a) 
 
Parameter Data 
Identification code Shelx 
Empirical formula C36 H50 F2 N6 Ni O4 
Formula weight 725.4943 
Temperature 296(2) K 
Wavelength 0.71073  A 
Crystal system Triclinic 
Space group P -1 
Unit cell dimensions  
   a = 9.2344(8) A α = 88.754(3)o 
   b = 11.9541(10) A β = 82.042(3)o 
   c = 17.6358(15) A γ = 86.611(3)o 
Volume 1924.5(3) A3 
Z 2 
Density (calculated) 1.172 mg/m3 
Absorption coefficient 0.559 mm-1 
F(000) 712 
Crystal size 0.380 x 0.280 x 0.200 mm3 
Theta range for data 
collection 
2.054 to 26.998o 
Index ranges -10<=h<=11, -15<=k<=15, 
-22<=I<=22 
Reflections collected 28586 
Independent reflections 8273 [R(int) = 0.0377] 
Completeness to theta 
= 25.242o 
99.2% 
Refinement method Full-matrix least-squares 
on F2 
Data / restrains / 
parameters 
8273 / 0 / 469 
Goodness-of-fit on F2 1.040 
Final R indices 
[1>2sigma(1) 
R1 = 0.0788, wR2 = 
0.2356 
R indices (aa data) R1 = 0.1027, wR2 = 
0.2581 
Extinction coefficient n/a 
Largest diff. peak and 
hole 
1.705 and -0.637 e.A-3 
 
The co-ordination sphere around nickel cation 
was octahedral with basal plane A 
(N1/N2/N3/N4/N5/N6) of six nitrogen atoms from 
three molecules of ethylene-diamines (1,2-
diaminoethane). The structure contained two 
independent flurbiprofen anions and central tris 
(ethylene-diamine) nickel cation in the crystal 
structure. The structure was stabilised by 
intermolecular and intramolecular hydrogen 
bonds (N-H….O) (Figure 3). 
 
 




The FT-IR analysis of the compounds was in 
agreement with relevant literature on complex 
formation. Discussion was focused on the 
important peaks. Appearance of bands in the 
range 1547 - 1692 cm-1 is usually attributed to -
OH belonging to the –COOH functional group, 
while IR peaks which appear in the range of 
1419 - 1487 cm-1 belong to aromatic =CH- group. 
The bands within 451 - 462 cm-1 range are 
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assigned to metal-oxygen bonds (M←O), while 
bands within the range 507 to 594 cm-1 are 
attributed to the ῡ (M←N) metal-nitrogen bonds. 
IR analyses of the complexes revealed that ῡ 
(M←N) metal nitrogen peaks were not observed 
for 3a-3c which were synthesized from transition 
metals and ligands only. However, when 1, 2-
diaminoethane and 1, 3-diaminopropane were 
added to 3a-3c  complexes to form 4a-4c and 
5a-5c, the ῡ (M←N) metal nitrogen peaks 
appeared in the range of 507 - 594 cm-1, which 
confirmed chelation between metal and the 
nitrogen atoms of 1, 2-diaminoethane and 1, 3-
diaminopropane. Furthermore, ῡ (M←H2O) and ῡ 
(M←O) peaks disappeared in these complexes. 
 
UV/Vis spectra and magnetic susceptibility  
 
The electronic spectra of 3D-transition metal 
complexes were recorded in 10-3 to 10-5 M 
solutions of each metal complex in DMSO, in a 
wavelength range of 200-800 nm. The electronic 
spectra of Ni(II) complexes showed that 3a had 
three absorption peaks at 12713, 18274 and 
27237 cm-1; 4a had three absorption peaks at 
18532, 22247 and 29408 cm-1, while  5a 
produced three absorption peaks at 18521, 
22234 and 29397 cm-1. These peaks were 
expected due to 3A2g(F) →3T2g(F), 3A2g(F) 
→3T1g(F) and 3A2g(F) →3T2g(P) transitions which 
tallied with the octahedral symmetry of the 
complex. The calculated B.M. values of nickel 
complexes were 1.8, 1.9 and 1.9, which agreed 
with the distorted octahedral geometry of nickel 
complexes. 
 
The electronic spectra of Co(II) complexes 
showed that 3b exhibited significant bands at 
14467, 21332 and 17384-17565 cm-1, while 4b 
produced  high-energy bands at 14797, 19456 
and 21447-21673 cm-1. High energy bands for 
(5b) were observed at 14782, 21427-21616 cm-1, 
along with energy band at 19435 cm-1 which 
were due to  4T1g(F) → 4T2g(F) and 4T1g(F) → 
4T1g(P) transitions for a low-spin octahedral 
geometry. The calculated B.M. values of cobalt 
complexes were 1.8 and 1.9 and 1.9, which 
agreed with the octahedral geometry of cobalt 
complexes. The electronic spectra of Mn(II) 
complex showed different sharp peaks in the 
range of 16645, 20755, 24532 and 27234cm-1 for 
3c; 18354, 20862, 25568 and 29421cm-1 for 4c, 
and 18366, 20887, 25589 and 29438cm-1 for 5c. 
These peaks were due to 4T1g(G) → 4T2g(G), 
4T2g(G) →4Eg(G), 4T1g(G) → 4A1g,4Eg(D) →4T1g(P) 
transitions which are expected in distorted 
octahedral symmetry of complexes. The 
calculated B.M. values of manganese complexes 
were 1.8, 2.1 and 2.1, which were in agreement 





The actual percentage of C, H and N obtained for 
all the synthesized transition metal (II) complexes 
of flurbiprofen were compared with the calculated 
values for their suggested structures. The found 
and calculated values of all the synthesized 
flurbiprofen metal (II) complexes are given in 
Table 2. The found and calculated values were 
within the acceptable range (± 0.03-0.95), which 
provided evidence for the formation of the 





Molar conductivities of the synthesized metal 
complexes were evaluated at room temperature. 
All the solutions of metal complexes were 
prepared at a concentration of (1x10-3M). It was 
found that the molar conductivities of the 
synthesized flurbiprofen metal complexes (3a-3c) 
were 31, 29 and 26 Ω-1cm2mol-1, which indicated 
their non-ionic nature. 
 
However, after adding ethylene-diamine (1, 2-
diaminoethane) and propane-diamine (1, 3-
diaminopropane) to these transition metal 
complexes to form their respective complexes 
(4a-4c) and tris(1,3-diaminopropane) metal 
flurbiprofen complexes (5a-c), the conductivities 
of these metal complexes increased many folds. 
The conductivities were 186, 174, 163 Ω-
1cm2mol-1 for 4a-4c, and 175, 169, 153 Ω-
1cm2mol-1 for 5a-5c. The significant increases in 
conductivity of the tris-diamine-derived 
flurbiprofen metal complexes indicate that the 




The anti-cholinesterase activities of all the 
synthesized complexes were compared as 
shown in Table 3. Metal complexes derived from 
1, 2-diaminoethane (4a-4c) were more potent, 
with lower IC50 values against both AChE and 
BChE, when compared to 1, 3-diaminopropane 
(5a-5c). Nickel complexes were the most active, 
and had the least IC50 values, when compared to 
cobalt and manganese complexes. Among all the 
synthesized complexes, 4a produced the most 
significant inhibitory activities, with IC50 of 2.9 
±0.16µM for AChE, and IC50 of 11.4 ±0.58 µM for 
BChE. For 5a, the IC50 values for AChE and 
BChE were 3.80 ±0.60 and 13.30 ± 1.74 µM, 
respectively, when compared to the standard 
drug galantamine. 
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IC50 (µM)a Selectivity 














































A* Galantamine 4.0±0.10 15.0±0.67 3.7 
aValues are expressed as mean ± S.E.M. of results from at least three experiments; bSI = IC50 ratio 




In this study, novel tris-diamine-derived transition 
metal complexes of Ni(II), Co(II) and Mn(II)  were 
synthesized and characterized by different 
spectroscopic techniques. X-ray crystallography 
of 4a showed that co-ordination sphere around 
nickel cation was octahedral. The complexes 
were six-coordinated and surrounded by two 
flurbiprofen and three ethylene-diamine ligands 
showing a distorted octahedral environment with 
a metal center formed by Ni, Co and Mn. There 
were two independent flurbiprofen deprotonated 
monodentate ligands coordinated to nickel ion 
via a carboxylate oxygen anions and central 
tris(1,2 diaminoethane) nickel cation in the 
crystal structure. Intermolecular and 
intramolecular hydrogen bonds (N-H…..O) were 
also present in crystal structure of 4a, which 
stabilized the molecule. The bond distances were 
close to those of previously reported nickel 
complexes with NSAID [20].  
FTIR analysis confirmed the chelation between 
metal and oxygen ῡ(M←O), and peaks appeared 
in the range of 451 - 462 cm-1 for simple 
flurbiprofen metal complexes, and in the range of 
504-594 cm-1 for metal-nitrogen ῡ(M←N) in 
diamine-derived metal complexes. Magnetic 
susceptibility and UV/Vis also suggested 
distorted octahedral geometry for all the 
complexes. Conductivity measurements 
confirmed non-ionic nature of 3a-3e, and ionic 
nature of 4a-4e and 5a-5e. Results from 
elemental analysis were also consistent with the 
proposed structures of the metal complexes. 
 
Metals play important roles in different biological 
functions, and are important components of 
many enzymes. The biological roles of metals 
and their complexes with Mn(II),Co(II), and Ni(II) 
are of interest because chelation of metals 
strongly influence the nature and magnitude of 
pharmacological activities by interacting with 
active sites of enzymes [21]. Thus, metal 
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chelation is used in many neurobiological and 
pharmaceutical applications for the treatment of 
a neurological disease such as AD [20, 22]. The 
metal ions in the current study were studied in 
order to investigate potential synergism or 
structural interaction with the carboxylic group of 
flurbiprofen.  
 
It was observed that diverse ligands acted as co-
ligands. The existence of co-ligands is of 
biological importance because it potentially 
contributes to enhanced biological activity, and 
provides novel compounds of structural interest 
[23]. This is in agreement with the results of the 
present study in which metal complexes of 
cobalt, manganese and nickel derived from 1,2-
diaminoethane (4a-4c), 1,3-diaminopropane (5a-
5c) and flurbiprofen were found to be more 
potent, with the least IC50 values against AchE 
and BChE, when compared to simple metal 
flurbiprofen complexes. However, nickel 
complexes possessed higher activity, and had 
the least IC50 values, when compared to cobalt 
and manganese. Among the synthesized 
complexes, Ni (C2H8N2)3 (fp)2 (4a) and Ni 
(C3H10N2)3 (fp)2 (5a) showed significant inhibitory 
activities against AChE and BChE, with low IC50 
values of 2.9±0.16, 11.4±0.58 and 3.8±0.60, 
13.3±1.74, respectively.  
 
The inhibition of AChE by the complexes is 
similar to the inhibition of γ-secretase (gamma 
secretase), an enzyme responsible for the 
production of amyloid-β peptides (Aβ) involved in 
AD. It has been revealed through computational 
studies that the number of aliphatic rings, relative 
number of double bonds and nitrogen atoms 
connected to heavy atoms with single bonds, are 
important features for inhibition of gamma 
secretase for slowing down the pathological 
progression of AD. This is due to electronegative 
substitution on aryl rings, which increases the 
value of partial equalization of orbital 
electronegativities (PEOEs), and substitution of 
acyclic amines with N-substituted cyclic amines 
which improves γ-secretase inhibition [24]. 
 
Moreover, the superior inhibition in the case of 
nickel was due to the fact that it has better 
chelating properties, better bonding to an ionic 
group, less steric hindrance and more available 
coordination sites [13]. These results are 
consistent with findings from studies on metal 
complexes of nickel and copper with 
ethylenediamine and glycine, where nickel 
chelates exerted significant inhibition due to 
availability of coordination sites in the metal 
which are more important than chelate charge for 




Mixed ligand-derived metal complexes are more 
active than simple metal flurbiprofen complexes. 
In addition, nickel complexes are most active in 
inhibiting AChE and BChE, with minimal IC50 
values relative to cobalt and manganese 
complexes. The findings also reveal the 
therapeutic potential of the synthesized 
complexes as potential drug candidates for the 
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